Lactobacillus gasseri 관련 Gastroesophageal Reflux Disease (GERD)
DEmerging evidence from Japanese studies. May reduce acid-related symptoms. Not yet replicated in Western populations.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dgasseri\u0026condition\u003Dgerd';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
결론
Emerging evidence from Japanese studies. May reduce acid-related symptoms. Not yet replicated in Western populations.
Key Study Findings
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
효과: None
None
대상 집단: patients with IBS from 32 RCTs evaluating 10 probiotic strains
In Vitro
Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in …
Dose: None
vs: H. pylori infection without lactobacilli
Outcome: ADAM17, HBEGF, TGF-alpha expression
효과: None
None
대상 집단: AGS gastric epithelial cells and mouse model
In Vitro
The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of …
Dose: 50 μg/ml
vs: None
Outcome: Inflammatory markers
효과: None
None
대상 집단: None
Other
Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter …
Dose: None
vs: None
Outcome: Inflammatory markers
효과: None
None
대상 집단: Cancer patients
In Vitro
Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability …
Dose: None
vs: None
Outcome: inflammation markers
효과: None
None
대상 집단: Mice
Case-Control
n=178
Oral and gastric microbiome in relation to gastric intestinal metaplasia.
Dose: None
vs: None
Outcome: Oral/gastric microbiome associations with IM
효과: None
None
대상 집단: Gastric intestinal metaplasia cases and matched controls
Key Statistics
3
연구
300
참여자
↑
Positive
D
등급
Referenced Papers
Journal of clinical …
2026
International journal of …
2025
Microbial pathogenesis
2024
8 인용
Helicobacter
2024
5 인용
International journal of …
2023
9 인용
International journal of …
2022
59 인용
BMC microbiology
2022
28 인용
Food & function
2022
19 인용
Probiotics and antimicrobial …
2021
30 인용
Comparative immunology, microbiology …
2019
72 인용
BMJ open gastroenterology
2019
14 인용
Digestion
2017
67 인용
Gastroenterology research and …
2016
38 인용
Helicobacter
2015
26 인용
PloS one
2014
171 인용
Frontiers in microbiology
2014
78 인용
Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health.
Review
FEMS microbiology reviews
2013
196 인용
Journal of food …
2012
56 인용
Journal of clinical …
2012
37 인용
Letters in applied …
2010
126 인용
Journal of medicinal …
2010
19 인용
Probiotics and antimicrobial …
2010
9 인용
Helicobacter
2009
48 인용
Cellular microbiology
2006
50 인용
Letters in applied …
2006
26 인용
Journal of gastroenterology …
2003
77 인용
The Journal of …
2001
309 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 1-10 billion CFU/day
- gerdsupport:
- 1-5 billion CFU/day
- hpylorisupport:
- 100 million CFU/day (LG21 strain, yogurt form) for 8-12 weeks
상한량: Well-tolerated up to 10 billion CFU/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| 50 μg/ml | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Neutral | 178 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
권장 복용 시간: Before meals or with meals; yogurt form taken with food
Safety & Side Effects
보고된 부작용
- ⚠ Mild gas during initial use
- ⚠ Occasional loose stools
- ⚠ Rare abdominal discomfort
- ⚠ Very rare: bacteremia in immunocompromised individuals
알려진 상호작용
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Proton pump inhibitors (altered gastric pH may affect colonization)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
일일 최대 섭취 허용량: Well-tolerated up to 10 billion CFU/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does Lactobacillus gasseri help with Gastroesophageal Reflux Disease (GERD)?
Based on 3 studies with 300 participants, there is preliminary evidence that needs more research that Lactobacillus gasseri may support Gastroesophageal Reflux Disease (GERD) management. Our evidence grade is D (Very Early Research).
How much Lactobacillus gasseri should I take for Gastroesophageal Reflux Disease (GERD)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus gasseri?
Reported side effects may include Mild gas during initial use, Occasional loose stools, Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus gasseri and Gastroesophageal Reflux Disease (GERD)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 3 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Gastroesophageal Reflux Disease (GERD)
Lactobacillus gasseri 다른 건강 상태에 대한 근거
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.